Eletriptan Pfizer.

Paul J L M Strijbos, Andrew A Parsons, Anders Fugelli

Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, Third Avenue, Harlow, Essex, CM19 5AD, UK. Paul_J_Strijbos@GSK.com

Current opinion in investigational drugs (London, England : 2000) 2002 Sep

filter terms:

Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].

Citation

Paul J L M Strijbos, Andrew A Parsons, Anders Fugelli. Eletriptan Pfizer. Current opinion in investigational drugs (London, England : 2000). 2002 Sep;3(9):1359-68